Mixed bag in the US overnight, the biotech stocks being hit after Eli Lilly phase 3 tests for its alzheimer’s drug faltered. banks higher on expectations of a lift in rates in December 2017.
Post Views: 382
Mixed bag in the US overnight, the biotech stocks being hit after Eli Lilly phase 3 tests for its alzheimer’s drug faltered. banks higher on expectations of a lift in rates in December 2017.